At the year-end work conference held on December 31, 2020, Xu Jingren, Party Secretary and Chairman of Yangtze River Pharmaceutical Group, pointed out that during the "13th Five-Year Plan" period, Yangtze River people have undertaken their mission and have the courage to innovate and have achieved good results. In 2021, Yangtze River Pharmaceutical will draw up a new blueprint for the development of the "14th Five-Year Plan", adhere to the leadership of party building, fully integrate into the national strategy, strengthen innovation motivation, and promote stable and long-term high-quality development from a higher starting point.
During the "Thirteenth Five-Year Plan" period, Yangzijiang Pharmaceuticals actively responded to various challenges, won tough battles one after another, won one victory after another, and handed in a high-quality answer sheet.
Innovative achievements continue to emerge, and innovative drug research and development accelerate the transformation. After years of accumulation, Yangtze River Pharmaceutical has made substantial progress in a number of innovative products. Generic drugs and consistency declarations continue to lead. The research and development of traditional Chinese medicines are followed up simultaneously. The health industry and the intelligentization of traditional Chinese medicines are accelerated. The innovative development of products based on classic famous prescriptions has cleared and retired. The thermal pellets were successfully launched on the market. At the same time, breakthroughs in marketing innovation have opened up new sales channels, new products, new models, and new businesses have been revitalized, and the stamina for corporate development has been further enhanced.
Quality management strives for perfection and has achieved fruitful results. Yangzijiang Pharmaceutical has established and improved the “four-in-one” management system of quality, brand, safety, and environmental protection, and implemented the chief quality officer system. Two quality standards were upgraded to local standards in Jiangsu Province, and one quality management achievement won the China Management Science Award.
In 2020, Yangzijiang Pharmaceutical ranked 27th in the "Report on Global 1000 Pharmaceutical Companies" published by Torr eya, a global investment bank; for the third time, it was ranked as both in brand strength and brand value in the pharmaceutical and health sector of the "China Brand Value List" 1. Won the total number of first prizes for QC achievements in China's pharmaceutical industry "16 consecutive championships", and won 4 international QC platinum awards.
These brilliant achievements have provided strong support for the continued high-quality development of Yangtze River Pharmaceutical during the 14th Five-Year Plan. According to reports, during the "14th Five-Year Plan" period, Yangtze River Pharmaceutical will adhere to the problem-oriented approach and do the following: first, speed up the development of innovative drugs, optimize human resources, and guide management cadres to continuously improve their vision, ability and level; second, adhere to stability Strive for progress, implement the new development concept, actively integrate into the national strategy, and deepen the supply-side structural reform; the third is to promote the overall upgrade of human resources, quality, safety, and environmental protection management, and to strengthen the new momentum of the development of subsidiaries; the fourth is to vigorously expand new business formats, New businesses and new models have taken new steps in international development.
